Načítá se...
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors...
Uloženo v:
| Vydáno v: | Nat Commun |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7260192/ https://ncbi.nlm.nih.gov/pubmed/32471999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16142-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|